AG
FLNA

Algert Global’s Filana Therapeutics FLNA Stock Holding History

Algert Global’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,531
Closed -$219K – 1100
2021
Q3 		$219K Buy
+3,531
New +$295K 0.03% 878
2014
Q3 		– Sell
-2,778
Closed -$112K – 321
2014
Q2 		$112K Buy
+2,778
New +$103K 0.07% 272

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Algert Global's FLNA Position: Q4 2021 in Review

Algert Global sold out of Filana Therapeutics (FLNA) in Q4 2021, closing a stake of 3,531 shares — an estimated $219K sold.

Algert Global first reported a position in FLNA in Q2 2014 and held it in 2 quarters. The position peaked at $219K in Q3 2021. 171 funds tracked by Wall St. Rank hold FLNA as of Q4 2021.

  • Algert Global reported no remaining Filana Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Algert Global sold 3,531 Filana Therapeutics shares in Q4 2021, an estimated $219K.
  • Algert Global first reported a position in Filana Therapeutics in Q2 2014 and held it in 2 quarters.
  • Algert Global's Filana Therapeutics position peaked at $219K in Q3 2021.
  • 171 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2021.

Based on Algert Global's 13F filing for Q4 2021, filed 14 Feb 2022.